John P. Butler has bought stock on 2 days since Aug 2018

John P. Butler is the President, Chief Executive Officer, and Director of Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on developing and commercializing therapies for kidney disease patients. He joined Akebia in September 2013, leading its initial public offering in 2014, raising over $1 billion through equity offerings and license agreements, and orchestrating the 2018 merger with Keryx Biopharmaceuticals.(

Butler brings over 35 years of experience in the biopharmaceutical industry, including prior roles as CEO of Inspiration Biopharmaceuticals (2011-2013), where he facilitated a major asset sale to Baxter; SVP and President of Cardiometabolic & Renal at Genzyme (2009-2011), launching products like Renagel®, Renvela®, and Hectorol®; and commercial leadership at Amgen for Epogen®. He has served on boards including Relypsa, Inc., Zynerba Pharmaceuticals, Keryx Biopharmaceuticals (as Chairman), and Wavebreak Therapeutics, and chaired Kidney Care Partners (2020-2023) and the American Kidney Fund board.( Butler holds an undergraduate degree from Manhattan University and an MBA in Marketing Management from Baruch College (1994).( As a corporate insider, he recently sold 144,250 shares of AKBA stock on February 3, 2025, under a Rule 10b5-1 plan, retaining over 2.6 million shares, and received significant equity awards in January 2026.(

Written by Perplexity from public sources.